Department of Veterans Affairs decides to severely limit use of Avandia, once-popular drug for Type 2 diabetes, delivering another blow to maker, GlaxoSmithKline; decision is likely to further reduce sales of Avandia, once $2.2 billion franchise in US alone; sales of drug in US have declined by estimated 60 percent since May, when New England of Journal of Medicine published analysis questioning drug's safety; VA makes up about 8 percent of Avandia's sales
Department of Veterans Affairs decides to severely limit use of Avandia, once-popular drug for Type 2 diabetes, delivering another blow to maker, GlaxoSmithKline; decision is likely to further reduce sales of Avandia, once $2.2 billion franchise in US alone; sales of drug in US have declined by estimated 60 percent since May, when New England of Journal of Medicine published analysis questioning drug's safety; VA makes up about 8 percent of Avandia's sales
Department of Veterans Affairs decides to severely limit use of Avandia, once-popular drug for Type 2 diabetes, delivering another blow to maker, GlaxoSmithKline; decision is likely to further reduce sales of Avandia, once $2.2 billion franchise in US alone; sales of drug in US have declined by estimated 60 percent since May, when New England of Journal of Medicine published analysis questioning drug's safety; VA makes up about 8 percent of Avandia's sales
Department of Veterans Affairs decides to severely limit use of Avandia, once-popular drug for Type 2 diabetes, delivering another blow to maker, GlaxoSmithKline; decision is likely to further reduce sales of Avandia, once $2.2 billion franchise in US alone; sales of drug in US have declined by estimated 60 percent since May, when New England of Journal of Medicine published analysis questioning drug's safety; VA makes up about 8 percent of Avandia's sales
Department of Veterans Affairs decides to severely limit use of Avandia, once-popular drug for Type 2 diabetes, delivering another blow to maker, GlaxoSmithKline; decision is likely to further reduce sales of Avandia, once $2.2 billion franchise in US alone; sales of drug in US have declined by estimated 60 percent since May, when New England of Journal of Medicine published analysis questioning drug's safety; VA makes up about 8 percent of Avandia's sales
Department of Veterans Affairs decides to severely limit use of Avandia, once-popular drug for Type 2 diabetes, delivering another blow to maker, GlaxoSmithKline; decision is likely to further reduce sales of Avandia, once $2.2 billion franchise in US alone; sales of drug in US have declined by estimated 60 percent since May, when New England of Journal of Medicine published analysis questioning drug's safety; VA makes up about 8 percent of Avandia's sales
Department of Veterans Affairs decides to severely limit use of Avandia, once-popular drug for Type 2 diabetes, delivering another blow to maker, GlaxoSmithKline; decision is likely to further reduce sales of Avandia, once $2.2 billion franchise in US alone; sales of drug in US have declined by estimated 60 percent since May, when New England of Journal of Medicine published analysis questioning drug's safety; VA makes up about 8 percent of Avandia's sales
Department of Veterans Affairs decides to severely limit use of Avandia, once-popular drug for Type 2 diabetes, delivering another blow to maker, GlaxoSmithKline; decision is likely to further reduce sales of Avandia, once $2.2 billion franchise in US alone; sales of drug in US have declined by estimated 60 percent since May, when New England of Journal of Medicine published analysis questioning drug's safety; VA makes up about 8 percent of Avandia's sales
Department of Veterans Affairs decides to severely limit use of Avandia, once-popular drug for Type 2 diabetes, delivering another blow to maker, GlaxoSmithKline; decision is likely to further reduce sales of Avandia, once $2.2 billion franchise in US alone; sales of drug in US have declined by estimated 60 percent since May, when New England of Journal of Medicine published analysis questioning drug's safety; VA makes up about 8 percent of Avandia's sales
Department of Veterans Affairs decides to severely limit use of Avandia, once-popular drug for Type 2 diabetes, delivering another blow to maker, GlaxoSmithKline; decision is likely to further reduce sales of Avandia, once $2.2 billion franchise in US alone; sales of drug in US have declined by estimated 60 percent since May, when New England of Journal of Medicine published analysis questioning drug's safety; VA makes up about 8 percent of Avandia's sales
